Travere Therapeutics, Inc.
NASDAQ: TVTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Eric Dube
- Employees
- 385
- Headquarters
- San Diego, United States
- IPO year
- 2012
- Market cap
- $5.1B
- Website
- https://www.travere.com
Loading TVTX…
Loading profile data…Frequently asked questions about TVTX
What does Travere Therapeutics, Inc. (TVTX) do?
Travere Therapeutics, Inc., a biopharmaceutical firm headquartered in San Diego, California, was founded in 2008 with a mission to discover, develop, commercialize, and deliver treatments for rare diseases. The company adopted its current name in November 2020, previously operating as Retrophin, Inc. Its current product offerings include Chenoda...
Where does TVTX trade?
Travere Therapeutics, Inc. (TVTX) trades on the NASDAQ Global Market.
What sector is TVTX in?
Travere Therapeutics, Inc. (TVTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Travere Therapeutics, Inc.?
Eric Dube is the chief executive officer of Travere Therapeutics, Inc. (TVTX).
Where is Travere Therapeutics, Inc. headquartered?
Travere Therapeutics, Inc. is headquartered in United States.
Does TVTX pay a dividend?
Travere Therapeutics, Inc. (TVTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TVTX go public?
Travere Therapeutics, Inc. (TVTX) completed its initial public offering in 2012.